Director/PDMR Dealings

RNS Number : 9170U

Arecor Therapeutics PLC

04 August 2022

 

4 August 2022

Arecor Therapeutics plc

("Arecor" or the "Company" or the "Group")

Director/PDMR Dealings

and

Completion of the Acquisition of Tetris Pharma

Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical company advancing today's therapies to enable healthier lives, announces t hat further to the Placing and acquisition of Tetris Pharma, details of which were announced on 1 August 2022, pursuant to the Placing, the following Directors subscribed for an aggregate amount of £113,271 at the Placing Price of 300 pence per ordinary share.

Following General Admission today, the Placing and acquisition of Tetris Pharma have now completed.

The following Directors interests in Ordinary Shares are as follows:

N ame	Placing Shares acquired	Resultant shareholding following Admission	% of the Enlarged Share Capital
Sarah Howell ( Chief Executive Officer)	6,666	847,072.00	2.8%
Susan Lowther ( Chief Financial Officer)	3,334	139,849.00	0.5%
Andrew Richards ( Chair)	6,666	223,834.00	0.7%
Sam Fazeli ( Non-Executive Director)	7,756	115,708.00	0.4%
J eremy Morgan ( Non-Executive Director)	6,666	27,169.00	0.1%
Christine Soden ( Non-Executive Director)	6,667	19,167.00	0.1%
Total	37,755

The capitalised terms used in this announcement have the same meanings as in the announcement published by the Company at 7.00 a.m. on 1 August 2022 unless otherwise stated.

For more information, please contact:

Arecor Therapeutics plc	www.arecor.com
Dr Sarah Howell, Chief Executive Officer	Tel: [phone] Email: [e-mail]
Susan Lowther, Chief Financial Officer	Tel: [phone] Email: [e-mail]
Mo Noonan, Communications	Tel: [phone] Email: [e-mail]
Panmure Gordon (UK) Limited (NOMAD and Broker)
Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking)	Tel: [phone]
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Gray	Tel: [phone] Email: [e-mail]

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	a)  Sarah Howell b)  Susan Lowther c)  Andrew Richards d)  Sam Fazeli e)  Jeremy Morgan f)  Christine Soden
2	Reason for the notification
a)	Position/status	a)  Chief Executive Officer b)  Chief Financial Officer c)  Chair d)  Non-executive Director e)  Non-executive Director f)  Non-executive Director
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Arecor Therapeutics plc
b)	LEI	98450093D12I3A8DDD58
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of 1p each
	Identification code	ISIN: GB00BMWLM973
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			a)  300 pence b)  300 pence c)  300 pence d)  300 pence e)  300 pence f)  300 pence	a)  6,666 b)  3,334 c)  6,666 d)  7,756 e)  6,666 f)  6,667
d)	Aggregated information
	- Aggregated volume	37,755
	- Price	300 pence
e)	Date of the transaction	4 August 2022
f)	Place of the transaction	XLON

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical group transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™ , we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat ™ platform is supported by an extensive patent portfolio . 

For further details please see our website, www.arecor.com

 

END

 

 

DSHBKQBPOBKKPFK